Characterisation of trials where marketing purposes have been influential in study design: A descriptive study

Trials

Volumn 17, Issue 1, 2016, Pages

  Barbour, Virginia ^a   Burch, Druin ^b   Godlee, Fiona ^c   Heneghan, Carl ^d   Lehman, Richard ^e   Perera, Rafael ^f   Ross, Joseph S ^g   Schroter, Sara ^c  

^a GRIFFITH UNIVERSITY   (Australia)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c The BMJ ^*  (United Kingdom)

^d Centre for Evidence Based Medicine   (United Kingdom)

^e Department of Primary Care Health Science ^*  (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

General Medical Journals; Marketing trials; Publication; Trials

Indexed keywords

ARTICLE; CLINICAL STUDY; CLUSTER ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FUNDING; HUMAN; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; MARKETING; METHODOLOGY;

HUMANS; MARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84958938373     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-1107-1     Document Type: Article

References (13)

1. Krumholz SD, Egilman DS, Ross JS. Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial. Arch Intern Med. 2011;171(12):1100-7.
2. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: review of internal documents. Ann Intern Med. 2008;149:251-8.
3. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med. 1994;331(20):1350-3.
4. Sox HC, Rennie D. Seeding trials: just say "no". Ann Intern Med. 2008;149(4):279-80.
5. McMaster Plus. http://hiru.mcmaster.ca/hiru/HIRU_McMaster_PLUS_Projects.aspx Accessed 11 November 2015.
6. Barbour V, Burch D, Godlee F, Heneghan C, Lehman R, Ross J, et al. Characterization of trials designed primarily for marketing purposes rather than addressing genuine clinical questions: a descriptive study [abstract].2013. http://www.peerreviewcongress.org/2013/Plenary-Session-Abstracts-9-10.pdf p31. Accessed 14 Jan 2015.
7. Reynolds A, Richards G, de la Iglesia B, Rayward-Smith V. Clustering rules: a comparison of partitioning and hierarchical clustering algorithms. J Math Model Algorithms. 2006;5:475-504.
8. Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987;20:53-65.
9. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2(5):e138. doi: 10.1371/journal.pmed.0020138.
10. Angell M. The truth about drug companies: how they deceive us and what to do about it. New York: Random House; 2005.
11. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1-79. doi: 10.3310/hta17100.
12. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet.1988;2(8607):349-60.
13. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985;6(7):556-85.